BioSpace News Archive

Business

Industry Veteran Tony Coles Tapped to Helm Pfizer Spinout Cerevel Therapeutics

Nearly one year after it was launched by Pfizer and Bain Capital, Cerevel Therapeutics has tapped industry veteran Tony Coles as its chief executive officer.

September 9, 2019
·
3 min read
·
Alex Keown
Bio NC

Why You Should Look for a New Job Before You Hate Your Old One

Do you wake up every morning dreading going to work? If this happens to you even once a week, it may be time to start looking for a new gig.

September 9, 2019
·
2 min read
·
Laura Brothers
Drug Development

ACADIA Halts Psychosis Trial Early After Nuplazid Hits the Mark

Shares of ACADIA Pharmaceuticals are up nearly 70% after the company announced it halted a Phase III psychosis trial early after its Parkinson’s disease drug Nuplazid hit primary endpoints and positioned the company to seek another potential regulatory approval.

September 9, 2019
·
2 min read
·
Alex Keown
Bio NC

6 Things to Negotiate in a Job Offer Besides Money

There are things to negotiate in a job offer other than just money. You can begin your negotiation using this comprehensive guide that will tell you what to do and what not to.

September 9, 2019
·
2 min read
·
Laura Brothers
Deals

Vifor Pharma announces the initiation of S&P credit rating coverage with an investment grade rating

Vifor Pharma announced that Standard & Poor’s assigned a BBB- credit rating with stable outlook to Vifor Pharma.

September 9, 2019
·
1 min read
Drug Development

Poxel Announces Symposium Presentation for Imeglimin at 55th Annual Meeting of the European Association for the Study of Diabetes

Detailed Imeglimin Phase 3 TIMES 1 results to be presented at EASD; session chaired by Ralph DeFronzo, M.D., leading academic diabetes expert

September 9, 2019
·
5 min read
Policy

SpePharm AG Wins Case Against Eisai Inc. in United States District Court for District of Delaware

SpePharm AG, a subsidiary of Norgine B.V., announced that the United States District Court for the District of Delaware ruled on 4th September 2019 in favour of SpePharm in its proceeding against Eisai Inc., upholding SpePharm’s licensed rights for SALAGEN® through April 2026.

September 9, 2019
·
2 min read
Business

Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor

Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered non-small cell lung cancer and thyroid cancer patients who may be suitable for LOXO-292, Lilly’s RET inhibitor

September 9, 2019
·
3 min read
Drug Development

Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer

Eli Lilly and Company presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib[1] monotherapy, also known as LOXO-292, for the treatment of RET fusion-positive non-small cell lung cancer.

September 9, 2019
·
8 min read
Over a quarter of Canadian men fear discussing mental health at work could risk their job

One in four Canadian men (28 per cent) fear their job could be at risk if they discussed their mental health at work, according to new research by Movember.

September 9, 2019
·
7 min read